

MESOBLAST APPOINTS RENOWNED CARDIOVASCULAR SURGEON DR ERIC A. ROSE TO BOARD OF DIRECTORS

Melbourne, Australia; 17 April 2013: Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced the appointment of Dr Eric A. Rose, a world leader in cardiovascular medicine, to its Board of Directors. Dr Rose is currently Chairman and CEO of SIGA Technologies and Executive Vice President, Life Sciences, at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman.

From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine, which has an extensive portfolio of research focused on evaluation of complex medical technologies in cardiovascular disease, cancer, diabetes mellitus, and neurologic disease. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 to 1992, he led the Columbia-Presbyterian heart transplantation program, during which time it became the most active program in the United States. Dr Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984. He has investigated many alternatives to heart transplantation, including cross species transplantation and man-made heart pumps. He is also Chairman of the Board of Circulite, Inc., a developer of advanced left ventricular assist devices. Dr Rose has authored or co-authored more than 300 scientific publications and has received more than \$25 million in National Institutes of Health support for his research.

Dr Rose said he viewed his appointment to the Mesoblast Board as a natural fit for his experience, knowledge and skills.

"Mesoblast is clearly the leader in the most exciting medical field in the world today - regenerative medicine – with the potential to set new paradigms in medicine" Dr Rose said.

Mesoblast Chairman, Mr Brian Jamieson, said: "I am delighted that Dr Rose has accepted the appointment and I am certain that his diverse professional expertise will make a significant and very valuable contribution to Mesoblast".

Mesoblast Limited

Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including

Mesoblast Limited
ABN 68 109 431 870
www.mesoblast.com

Corporate Headquarters
55 Collins Street
Level 39
Melbourne 3000
Victoria Australia
T +61 3 9639 6036
F +61 3 9639 6030

United States Operations
505 Fifth Avenue
Level 3
New York, NY 10017
USA
T +1 212 880 2060
F +1 212 220 2061

Asia
20 Biopolis Way
#05-01 Centros
Biopreneur 3
SINGAPORE 138668
T +65 6570 0635
F +65 6570 0176

inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney disease, orthopedic spine conditions, and cardiovascular disorders. www.mesoblast.com

For further information, please contact:

Julie Meldrum

Global Head of Corporate Communications

T: + 61 3 9639 6036

E: julie.meldrum@mesoblast.com

Mesoblast Limited
ABN 68 109 431 870
www.mesoblast.com

Corporate Headquarters
55 Collins Street
Level 39
Melbourne 3000
Victoria Australia

T +61 3 9639 6036
F +61 3 9639 6030

United States Operations
505 Fifth Avenue
Level 3
New York, NY 10017
USA

T +1 212 880 2060
F +1 212 220 2061

Asia
20 Biopolis Way
#05-01 Centros
Biopreneur 3
SINGAPORE 138668

T +65 6570 0635
F +65 6570 0176